Less Ads, More Data, More Tools Register for FREE

Pin to quick picksIxico Regulatory News (IXI)

Share Price Information for Ixico (IXI)

Share Price is delayed by 15 minutes
Get Live Data
8.65    0.00 (0.00%)
Bid:
8.30
Ask:
9.00
Spread: 0.70 (8.434%)
Market Cap: £18.86m
IXI Live PriceLast checked at - London Stock Exchange

Intraday Ixico Share Chart

Director/PDMR Shareholding

11 Sep 2019 07:00

RNS Number : 8752L
IXICO plc
11 September 2019
Β 

11 September 2019

Β 

IXICO plc

("IXICO" or the "Company")

Β 

PDMR share option exercise and TVR

IXICO plc (AIM: IXI), the data analytics company delivering insights in neuroscience, announces that on 10 September 2019, John Hall, SVP Corporate Development, exercised 87,647 share options in the Company resulting in the allotment of new ordinary shares. 50,000 of these shares are allotted at a price of 36.5p and 37,647 of these shares are allotted at a price of 49p.

Β 

John Hall is interested in 183,094 Ordinary Shares, representing 0.4 per cent of the enlarged issued share capital of the Company following the exercise of options.

Β 

Application has been made to the London Stock Exchange for the admission to trading on AIM of 87,647 new ordinary shares of 1p each ("New Shares") to satisfy the exercise of options. The New Shares are expected to be admitted to trading on AIM on 16 September 2019.

Β Total voting rights

Application has been made for admission to trading on AIM of 87,647 New Shares. Admission of the New Shares on AIM is expected to become effective at 8.00a.m. on 16 September 2019, following which there will be in total 46,902,294 ordinary shares in the capital of the Company in issue, each carrying equal voting rights.

This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, IXICO under the FCA's Disclosure and Transparency Rules.

Β 

Β 

1

Β 

Details of the person discharging managerial responsibilities / person closely associated

Β 

a)

Β 

Name

Β 

Β 

John Hall

Β 

2

Β 

Reason for the notification

Β 

a)

Β 

Position/status

Β 

Β 

SVP Corporate Development

b)

Β 

Initial notification /Amendment

Β 

Β 

Initial notification

3

Β 

Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor

Β 

a)

Β 

Name

Β 

Β 

IXICO plc

b)

Β 

LEI

Β 

Β 

2138005M1F59O6HWSA97

4

Β 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted

Β 

Β 

a)

Β 

Description of the financial instrument, type of instrument

Ordinary Shares in IXICO plc

Identification code

GB00BCLY7L40

Β 

b)

Β 

Nature of the transaction

Β 

Β 

Exercise of share options

c)

Β 

Price(s) and volume(s)

Β 

Β 

Β 

Β 

Β 

Price(s)

Volume(s)

Β 

Β 

49p

37,647

Β 

Β 

36.5p

50,000

Β 

Β 

Β 

Β 

Β 

d)

Β 

Aggregated information

- Aggregated volume

87,647 shares

- Price

41.9p

e)

Β 

Date of the transaction

Β 

Β 

10/09/19

f)

Β 

Place of the transaction

Β 

Β 

Outside of a trading venue

Β 

IXICO plc

+44 (0) 20 3763 7498

Giulio Cerroni, Chief Executive Officer

Grant Nash, Chief Financial Officer

Cenkos Securities PLC (Nominated adviser and sole broker)

+44 (0) 20 7397 8900

Giles Balleny / Max Gould (Corporate Finance)

Michael F Johnson / Russell Kerr (Sales)

Optimum Strategic Communications

Β +44 (0) 203 950 9144

Mary Clark / Supriya Mathur

ixico@optimumcomms.com

Β 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.
Β 
END
Β 
Β 
DSHEBLFFKKFXBBF
Date   Source Headline
20th Aug 20195:38 pmRNSDirector/PDMR Shareholding
19th Aug 20194:40 pmRNSSecond Price Monitoring Extn
19th Aug 20194:35 pmRNSPrice Monitoring Extension
19th Aug 20197:00 amRNSTrading Update
9th Aug 20197:00 amRNSIXICO provides update on new & current contracts
23rd Jul 201911:05 amRNSSecond Price Monitoring Extn
23rd Jul 201911:00 amRNSPrice Monitoring Extension
11th Jul 20197:00 amRNSDirector and PDMR share purchase
10th Jun 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
31st May 20197:00 amRNSHolding(s) in Company
22nd May 20197:00 amRNSHalf Yearly Report to 31 March 2019
10th May 20197:00 amRNSNotice of Results
25th Apr 20197:00 amRNSUpdate for first half of year ending 31 March 2019
24th Apr 20197:00 amRNSAnnounces two new biopharmaceutical contracts
12th Apr 20197:00 amRNSChange of Adviser
19th Mar 20194:20 pmRNSHolding(s) in Company
18th Mar 201912:24 pmRNSDirector/PDMR Shareholding
13th Mar 20197:00 amRNSDirector/PDMR Shareholding
5th Mar 20197:00 amRNSLate phase clinical study in Huntington's disease
1st Mar 20197:00 amRNSIXICO chosen for new Medical Imaging & AI Centre
7th Feb 20197:00 amRNSAppointment of Chief Financial Officer
11th Dec 20187:00 amRNSDirectorate Change
4th Dec 20187:00 amRNSFinal Results
4th Dec 20187:00 amRNSScope expanded with top 10 biopharma company
15th Oct 20187:00 amRNSPre-Close Trading Update
21st Sep 20184:46 pmRNSResult of General Meeting - Amended
21st Sep 201811:00 amRNSResult of General Meeting
11th Sep 20187:00 amRNSContract with top 10 global pharmaceutical company
3rd Sep 20187:00 amRNSProposed Capital Reorganisation
30th Aug 20187:00 amRNSContract expansion with biopharmaceutical company
21st Aug 20187:00 amRNSTrading Statement
13th Aug 20187:00 amRNSAgreement
13th Jun 20189:00 amRNSImplementation of Long Term Incentive Plan
12th Jun 20187:00 amRNSNotification of the cessation of a clinical trial
7th Jun 20189:47 amRNSIssue of Equity
31st May 20183:32 pmRNSHolding(s) in Company
31st May 20183:30 pmRNSHolding(s) in Company
30th May 201811:48 amRNSHolding(s) in Company
30th May 201811:45 amRNSHolding(s) in Company
30th May 20189:32 amRNSDirector/PDMR Shareholding
29th May 201812:08 pmRNSResult of General Meeting
23rd May 20183:29 pmRNSDirector/PDMR Shareholding
23rd May 20187:00 amRNSHalf-year Report
14th May 20187:00 amRNSNew contract with top 10 pharmaceutical company
10th May 20187:00 amRNSExpansion of two biopharmaceutical contracts
3rd May 20187:00 amRNSNotice of Interim Results

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.